Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02614547 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate SAGE-547 in Participants With Severe Postpartum Depression
A Phase 2 study, sponsored by Supernus Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
NCT02614547 is a Phase 2 study that has completed, run by Supernus Pharmaceuticals. The registered enrollment target is 21 participants.
The verdict
NCT02614547, a Phase 2 study, has completed, sponsored by Supernus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
Study Summary
This is a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the efficacy, safety, and pharmacokinetics of SAGE-547 Injection in adult female participants diagnosed with severe postpartum depression.
Interventions
- DRUG Placebo
- DRUG SAGE-547
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2015-12-15 |
| Est. Completion | 2016-06-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02614547
The ClinicalTrials.gov registry entry for NCT02614547 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Supernus Pharmaceuticals, which has 57 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02614547 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02614547 about?
NCT02614547 is a clinical study titled "A Study to Evaluate SAGE-547 in Participants With Severe Postpartum Depression". This is a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the efficacy, safety, and pharmacokinetics of SAGE-547 Injection in adult female participants diagnosed with severe postpartum depression.
What is the current status of trial NCT02614547?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2015-12-15. Estimated completion is 2016-06-22.
What interventions are being tested in trial NCT02614547?
The interventions under investigation include: Placebo (DRUG), SAGE-547 (DRUG).
Who is sponsoring clinical trial NCT02614547?
This trial is sponsored by Supernus Pharmaceuticals, which has 57 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.